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ABSTRACT
Introduction: Incretin-based therapies, that is,
glucagon-like peptide (GLP)-1 receptor agonists and
dipeptidyl peptidase (DPP)-4 inhibitors, are relatively
novel antihyperglycaemic drugs that are frequently
used in type 2 diabetes management. Apart from
glucose-lowering, these agents exhibit pleiotropic
actions that may have favourable and unfavourable
clinical consequences. Incretin-based therapies have
been associated with heart rate acceleration, heart
failure, acute renal failure and acute pancreatitis.
Conversely, these agents may reduce blood pressure,
glomerular hyperfiltration, albuminuria and hepatic
steatosis. While large-sized cardiovascular safety trials
can potentially identify the clinical significance of some
of these pleiotropic actions, small-sized mechanistic
studies are important to understand the (patho)
physiological rationale of these findings. The current
protocol describes a mechanistic study to assess
cardiovascular, renal and gastrointestinal effects, and
mechanisms of incretin-based therapies in type 2
diabetes.
Methods and analyses: 60 patients with type 2
diabetes will undergo acute and prolonged
randomised, double-blind, intervention studies.
The acute intervention will consist of intravenous
administration of the GLP-1 receptor agonist exenatide
or placebo. For the prolonged intervention, patients will
be randomised to 12-week treatment with the GLP-1
receptor agonist liraglutide, the DPP-4 inhibitor
sitagliptin or matching placebos. For each examined
organ system, a primary end point is defined. Primary
cardiovascular end point is change in resting heart rate
variability assessed by beat-to-beat heart rate monitor
and spectral analyses software. Primary renal end point
is change in glomerular filtration rate assessed by the
classic inulin clearance methodology. Primary
gastrointestinal end points are change in pancreatic
exocrine function assessed by MRI-techniques (acute
intervention) and faecal elastase-1 levels (12-week
intervention). Secondary end points include systemic
haemodynamics, microvascular function, effective renal
plasma flow, renal tubular function, pancreatic volume
and gallbladder emptying-rate.
Medical ethics and dissemination: The study is
approved by the local Ethics Review Board (VU
University Medical Center, Amsterdam) and conducted
in accordance with the Declaration of Helsinki and
Good Clinical Practice.
Trial registration number: NCT01744236.
INTRODUCTION
The global prevalence of type 2 diabetes has
reached alarming proportions, which is
strongly related to ageing and the obesity pan-
demic. Long-term intensive glycaemic control
has reduced the incidence of its microvascular
and macrovascular complications.1 2 However,
approximately 25% of patients with type 2
Strengths and limitations of this study
▪ This study includes three randomised, placebo-
controlled, double-blind clinical trials to assess
both acute and prolonged (12 weeks) effects of
incretin-based therapies on the cardiovascular,
renal and gastrointestinal system.
▪ Multiple secondary end points are studied in
order to provide an integrative view on the exam-
ined organ systems.
▪ The study may not be sufficiently powered to
draw conclusions on secondary end points.
▪ The duration of the prolonged intervention study
is 12 weeks and can, therefore, not be consid-
ered as a long-term exposure to the study drugs.
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diabetes do not reach glycaemic targets with currently
available antihyperglycaemic treatment options.3
Intensiﬁed treatment schedules may be associated with
adverse effects, including weight gain and hypoglycaemia.
Thus, besides improving and implementing public health
initiatives and preventive treatment strategies, the develop-
ment of novel antihyperglycaemic agents is needed. Over
the past decade, several antihyperglycaemic drug classes
have been introduced into the market. However, as with
every novel drug, there are potential safety risks that need
exploration in clinical trials. In spite of stringent regula-
tory rules that enforce the conduction of large-scaled
registration programmes, rare adverse effects may only
become apparent after marketing authorisation, when a
large group of patients has been treated for a longer
period of time. In addition to ongoing long-term cardio-
vascular safety trials for all novel antihyperglycaemic
drugs,4 there is a growing need to improve the postmar-
keting monitoring of potential risks and beneﬁts of these
drugs.
The 7th-Framework Programme funded European
project ‘Safety Evaluation of Adverse Reactions in
Diabetes’ (SAFEGUARD) is a pharmacovigilance project
designed to assess, quantify and understand safety
aspects of antihyperglycaemic drugs in type 2 diabetes,
with a focus on incretin-based therapies.5 The
SAFEGUARD-project consists of eight work packages,
including pharmacovigilance database studies, observa-
tional database studies, meta-analyses and mechanistic
studies. Here, we describe one of the protocols of the
mechanistic work package that explores some of
the pleiotropic actions that have been associated with
the use of incretin-based diabetes therapies.
GLP-1 and DPP-4
Incretin-based therapies are based on the gut-derived
incretin hormone glucagon-like peptide (GLP)-1. GLP-1
is released by intestinal L-cells on food ingestion and
regulates glucose homeostasis by inﬂuencing pancreatic
islet-cell function, including glucose-dependent stimula-
tion of insulin and suppression of glucagon secretion.6
However, native GLP-1 is rapidly metabolised by the
serine protease dipeptidyl peptidase (DPP)-4, leading to
a plasma half-life of ∼2 min. In type 2 diabetes, the
effect of this incretin on endocrine pancreatic function
is impaired. However, when native GLP-1 is administered
at pharmacological doses, it lowers fasting and postpran-
dial glucose, improves islet-cell function, delays gastric
emptying and induces bodyweight loss.7 Therefore,
GLP-1 was regarded as an attractive therapeutic option
for type 2 diabetes.8 To date, two incretin-based drug
classes have been developed and marketed: injectable
DPP-4-resistant GLP-1 receptor agonists which mimic the
effects of native GLP-1, and oral DPP-4 inhibitors which
prolong the actions of endogenously secreted GLP-1.9
Both incretin-based drug classes improve glycaemic
control in patients with type 2 diabetes, with minor risk
of hypoglycaemia in clinical practice.2 9
Pleiotropic effects of incretin-based therapies
Interestingly, the receptor for GLP-1 has been identiﬁed
in many non-pancreatic organ systems, such as the
heart, blood vessels, kidneys, gastrointestinal system and
central nervous system.10 11 It was, therefore, not unex-
pected to ﬁnd pleiotropic effects of GLP-1 and related
therapies. Although some of the pleiotropic actions of
incretin-based therapies may be beneﬁcial, these could
also cause adverse effects. For example, clinical use of
incretin-based therapies has been associated with heart
rate acceleration,12 heart failure,13 sporadic cases of
acute renal failure14 and acute pancreatitis.15–17
However, to date, a causal relationship between the use
of incretin-based therapies and the occurrence of
adverse effects is unclear (as type 2 diabetes per se is
associated with these conditions), and the underlying
mechanisms remain hitherto largely unexplored.
Incretin-based therapies and the cardiovascular system
GLP-1 receptor agonists have been associated with
resting heart rate acceleration (mean increase of 2–4
bpm),12 an established risk factor for cardiovascular and
all-cause mortality.18 The mechanisms underlying this
ﬁnding remain unclear, but alterations in cardiac auto-
nomic nervous system balance may be involved.19 20
Other potential mechanisms include changes in baro-
receptor sensitivity, natriuresis and reduced systemic vas-
cular resistance. Furthermore, although mechanistic
trials with incretin-based therapies showed improvement
in parameters associated with heart failure,21 22 recent
large-sized clinical trials revealed signs of increased hos-
pitalisation for heart failure with the DPP-4 inhibitors
saxagliptin and alogliptin, but not sitagliptin.13 23 24
Conversely, long-term GLP-1 receptor agonist adminis-
tration decreases systolic and diastolic blood pressure in
clinical trials.12 Moreover, it improves endothelial dys-
function, measured as ﬂow-mediated vasodilation,25 26
decreases macrophage foam cell formation and athero-
sclerosis in animals,27 and reduces carotid intimal-media
thickness in humans.28 Also, in animal models of myo-
cardial infarction, native GLP-1 administration reduced
infarction size29 and improved postinfarction myocardial
function.30 Similar cardiovascular improvements have
been noted in small-sized clinical studies.31–33
Incretin-based therapies and the renal system
Several case reports have described the occurrence of
acute renal failure in patients with type 2 diabetes
treated with incretin-based therapies.34 35 However, asso-
ciations between the use of incretin-based therapies and
renal failure were not supported by a large-sized data-
base analysis.36 Moreover, to date, clinical studies have
not given rise to concerns regarding renal adverse
events.
More recently, incretin-based therapies have been asso-
ciated with renoprotective properties. In animal models,
administration of GLP-1 and associated therapies
reduced systemic hypertension and albuminuria, and
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ameliorated renal damage, as veriﬁed by histology.37–40
In clinical studies, GLP-1 receptor agonists have been
associated with decreased development and progression
of albuminuria.41 42 Moreover, the clinical use of the
DPP-4 inhibitors saxagliptin and linagliptin were asso-
ciated with a glucose-independent reduction in albumin-
uria by approximately 25%.43–45 Collectively, these data
suggest a renoprotective effect with the use of incretin-
based therapies. However, the mechanisms by which
these antihyperglycaemic drugs may improve renal
outcome beyond glycaemic control are unclear, but may
involve improvements in body weight, blood pressure,
renal haemodynamics and albuminuria or lipid
proﬁles.40 46
Incretin-based therapies and the gastrointestinal system
GLP-1 receptor agonists and DPP-4 inhibitors have been
associated with acute pancreatitis,15–17 and histological
inﬂammatory changes of the pancreas have been shown
in rodents.47 Also, it has been hypothesised that incretin-
based therapies increase the risk of chronic pancreatitis
or pancreatic cancer.48 However, available data are con-
ﬂicting since many other studies fail to ﬁnd such adverse
effects with incretin-based therapies.49–51 As type 2 dia-
betes, and frequently associated comorbidities, is by
itself associated with pancreatitis, it is difﬁcult to distin-
guish the sole contribution of incretin-based therapies.
In contrast, beneﬁcial gastrointestinal effects of GLP-1
have been described, contributing to improved
glycaemic control trough decreased (postprandial)
glycaemic excursions.52 Moreover, mounting evidence
suggests therapeutic effects of incretin-based therapies
on gastrointestinal diseases, including non-alcoholic fatty
liver disease and irritable bowel syndrome.53 54
Mechanistically, GLP-1 peptide infusion decreases
stomach and bowel motility,55 and secretion of gastric
acid and exocrine pancreatic enzymes.56–58 Many of
these effects are likely to be mediated through changes
in vagal nerve function.56 In addition, the GLP-1 recep-
tor agonist exenatide reduces gallbladder emptying
rate.59 Hepatic effects of incretin-based therapies are still
unclear, but may include reduced endogenous glucose
and lipid production.60
Rationale and aim
Since a decade, GLP-1 receptor agonists and DPP-4 inhi-
bitors have been implemented for glucose-lowering
treatment of type 2 diabetes, and are now widely used in
clinical practice. However, there remain many gaps in
our understanding about various pleiotropic effects of
these antihyperglycaemic drugs. Importantly, incretin-
based therapy use has been associated with potential
adverse events, among others, affecting the cardiovascu-
lar, renal and gastrointestinal systems. While large-sized
randomised trials and database studies patients with type
2 diabetes will provide evidence on their clinical risks,
mechanistic studies are needed to identify the under-
lying mechanisms of the adverse effects. Therefore, the
current study aims to investigate the acute and pro-
longed effects of incretin-based therapies on the cardio-
vascular, renal and gastrointestinal system of patients
with type 2 diabetes.
METHODS AND ANALYSES
Study design
In order to assess acute and prolonged effects of
incretin-based therapies on the cardiovascular, renal and
gastrointestinal system, the current study integrates three
double-blind, randomised, placebo-controlled trials in
patients with type 2 diabetes. In the main parallel-group
study, 60 patients will be randomised and treated for
12 weeks with the GLP-1 receptor agonist liraglutide, the
DPP-4 inhibitor sitagliptin or matching placebos
(ﬁgure 1). After the baseline measurements of the
12-week intervention study, two acute intervention-
studies are performed to assess the effect of intravenous
administration of the GLP-1 receptor agonist exenatide
versus placebo: 1 parallel-group trial in all 60 patients to
assess acute cardiovascular and renal effects, and 1 cross-
over trial in a subset of 12 male patients to assess acute
pancreatic effects. Placebo is chosen as comparator for
all three trials, since this allows for the study of
drug-induced changes per se, instead of comparing
changes with an active comparator.
All examinations will be performed at the Clinical
Research Unit (CRU) of the Department of Internal
Medicine/Diabetes Centre of the VU University Medical
Center in Amsterdam, the Netherlands.
Outcome measures
Outcome measures will be studied after acute intraven-
ous drug-administration, and after 12 weeks of pro-
longed drug-intervention. In addition, predeﬁned
outcome measures will be evaluated after 2 and 6 weeks
of prolonged intervention (safety visits; table 1).
Outcome measures will be compared between the inter-
vention and placebo groups.
Cardiovascular outcomes
Primary outcome measure is resting heart rate variability
(HRV) assessed with a beat-to-beat heart rate monitor
and spectral analyses software. Secondary outcome mea-
sures include systemic haemodynamics (heart rate,
blood pressure, cardiac output, vascular resistance),
arterial stiffness and microvascular function (see online
supplementary table A).
Renal outcomes
Primary outcome measure is glomerular ﬁltration rate
(GFR), assessed by using the inulin clearance technique,
based on timed urine sampling. Secondary outcome mea-
sures include para-amino hippuric acid (PAH)-measured
effective renal plasma ﬂow, tubular function, and glom-
erular and tubular damage markers (see online supple-
mentary table B).
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Gastrointestinal outcomes
Primary outcome measure is pancreatic exocrine func-
tion. For the acute intervention study, this is measured
by exocrine secreted volume assessed by secretin-
enhanced MR cholangiopancreatography. For the
12-week study, this is measured by faecal elastase-1 levels.
Secondary outcome measures for the 12-week study
consist of exocrine pancreatic function, pancreatic struc-
ture/volume, gallbladder emptying, gastric emptying,
hepatic fat content and gastrointestinal damage markers
(see online supplementary table C).
Other and exploratory outcome measures
Additional outcome measures include body anthropo-
metrics, postprandial glucose excursions, glycated
haemoglobin, plasma lipids and body fat content (see
online supplementary table D). Moreover, urine, faeces
and blood (plasma and serum) are collected and stored
at −80°C for at least 15 years, to allow for determination
of additional biomarkers for potential future research
questions.
Participants
Volunteers with type 2 diabetes will be recruited using
established recruitment methods: (1) participants in the
previous studies of the VU University Diabetes Centre
will be contacted (if informed consent was obtained);
(2) advertisements in local newspapers, folders and
posters; (3) afﬁliated healthcare workers (internal medi-
cine, general practitioners) will inform patients of the
existence of this study; and (4) websites. After providing
extensive printed and oral information, a hand-signed
informed consent form will be attained by a clinical
research physician. Eligibility will be assessed during a
screening visit, comprising of a medical interview and
physical, blood, urine and ECG examination.
Postvoiding bladder residue will be assessed using ultra-
sonic bladder scan. Inclusion and exclusion criteria are
listed in box 1. After inclusion, participants will receive
an unique study number.
Intervention
Acute intervention studies
The GLP-1 receptor agonist exenatide (AstraZeneca,
London, UK) or placebo (isotonic 0.9% saline) will
be infused for 5 h. One dose of exenatide 10 µg will be
diluted in 46 mL isotonic 0.9% saline and 4 mL of
the participant’s blood to prevent binding of the drug to
the infusion material. For placebo, no study drug will be
added. The solution will be administered with a cali-
brated syringe pump at an infusion-rate of 50 ng/min
for 30 min; this is then followed by 25 ng/min infusion
for the remainder of the test procedures to target the
steady-state plasma concentrations of exenatide within
the therapeutic range (100–150 pg/mL).61
Twelve-week intervention study
The GLP-1 receptor agonist liraglutide (Novo Nordisk
A/S, Bagsværd, Denmark) and matching liraglutide-
placebo preﬁlled pens for subcutaneous use will be pro-
vided by Novo Nordisk. A dose increment scheme is
employed, in which patients will inject liraglutide/-
placebo at a dose of 0.6 mg once daily during the
ﬁrst week, 1.2 mg once daily during the second week, and
Figure 1 Study design: Subjects will be screened for eligibility. Included subjects will undergo a run-in period of at least
4 weeks after which the baseline end point measurements for the 12-week study and the acute intervention studies are
performed*. Subsequently, subjects are randomised for the prolonged intervention. After 2 and 6 weeks, a safety visit is
performed. At week 1 and 9, telephone follow-up is performed (not depicted). After 12 weeks of treatment, the end point
measurements are performed. *For the acute cardiovascular and renal study, subjects are randomised to exenatide or placebo.
For the acute pancreatic study, 12 patients will receive intravenous exenatide and placebo in a randomised cross-over design.
4 Smits MM, et al. BMJ Open 2015;5:e009579. doi:10.1136/bmjopen-2015-009579
Open Access
 o
n
 19 June 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2015-009579 on 19 November 2015. Downloaded from 
1.8 mg once daily during the remainder of the study.
Based on the participants’ tolerance to the trial product,
the time interval between the dose increments can be
extended, and drug dose can be reduced when regarded
to be clinically necessary. Subjects are instructed to inject
liraglutide/-placebo in the abdominal region, and always
at the same time of the day (preferably evening).
The DPP-4 inhibitor sitagliptin (Merck, Whitehouse
Station, New Jersey, USA) and matching sitagliptin-
placebo will be encapsulated by an independent
GMP-certiﬁed clinical research organisation (ACE
Pharmaceuticals BV, Zeewolde, the Netherlands).
Sitagliptin/-placebo 100 mg will be taken orally once daily
for 12 weeks, at the same time as the liraglutide/-placebo
injection. No dose escalation is needed for
sitagliptin/-placebo.
Participants randomised to the liraglutide-arm will
receive sitagliptin-placebo capsules, while participants
Table 1 Trial visits and end points
End point
Baseline Safety
Prolonged treatment
12-week
CV/R
CV/R
acute
CV/R
acute
PP GI MRI
MRI
acute* 2-week 6-week CV/R
CV/R
PP GI MRI
Cardiovascular
Resting heart rate variability X X X X X
Systemic haemodynamics X X X X X
Arterial stiffness X X X X X
Microvascular function X X X X X
Renal
Glomerular filtration rate X X X
Estimated glomerular filtration rate X X X X X
Effective renal plasma flow X X X
Fractional electrolyte excretion X X X
Urine osmolality X X X
Urine pH X X X
Glomerular damage parameter (albumin) X X X
Tubular damage parameters (KIM-1,
NGAL)
X X X
Body water percentage X X X
Gastrointestinal
Faecal elastase-1 X X
Faecal chymotrypsin X X
Lipase/amylase-levels X X X X X X
13C-MTG breath test X X
Pancreatic bicarbonate secretion X X X
Pancreatic structure/volume X X
Trypsinogen blood/urine X X X
Gallbladder emptying X X
Gastric emptying X X
Hepatic fat content X X
Plasma albumin/AST/ALT/yGT/ALP X X X
GI damage parameters (I-FABP, L-FABP,
calprotectin)
X X X
Microbiome X X
General
HbA1c X X
Fasting glucose X X
Postprandial glucose X X
Fasting lipid spectrum X X
Anthropometrics (length/height/waist/hip) X X X X
Body fat percentage X X
Subcutaneous and visceral fat volume X X
*The acute pancreatic MRI study is performed in a subset of 12 patients.
13c-MTG, 13C-labeled mixed triglyceride breath test; ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate
aminotransferase CV/R, cardiovascular and renal testing day; GI, gastrointestinal testing day; HbA1c, glycated haemoglobin; I-FABP,
intestinal fatty acid binding protein; L-FABP, liver-type fatty acid binding protein; PP, postprandial.
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randomised to the sitagliptin-arm will receive liraglutide-
placebo preﬁlled pens. Participants randomised to the
placebo-arm will receive liraglutide-placebo preﬁlled pens
and sitagliptin-placebo capsules.
Patients using sulfonylurea will be instructed to fre-
quently check their blood glucose levels, and in case of
clinically signiﬁcant hypoglycaemia, sulfonylurea dose will
be decreased based on the discretion of a research phys-
ician. In general, patients and caregivers will be instructed
not to change comedication without clinical need.
Randomisation
Randomisation will be performed by an institutional
trial pharmacist. For the acute studies, block randomisa-
tion will be performed with an allocation ratio of 1:1,
and a block-size of 6 (acute cardiovascular and renal
study) and 4 (acute pancreatic study). For the 12-week
study, block randomisation will be performed with an
allocation ratio of 1:1:1, and a block-size of
6. Stratiﬁcation will be applied, thereby evenly dividing
the number of patients receiving acute intravenous
administration of exenatide or placebo among the three
prolonged intervention groups (ﬁgure 2).
Blinding
Study medication will be provided by the trial pharma-
cist, and all study personnel and participating patients
will remain blinded with regards to the study medica-
tion. The blind shall not be broken, unless informa-
tion concerning the study medication is considered
medically necessary. If the investigator is unblinded,
study medication will be stopped and the participant
will be withdrawn from the study. The blind will be
broken by the institutional trial pharmacist after the
last patient has completed the last study visit and all
data are entered into the online clinical trial
database.
Compliance
For the 12-week study, participants will receive extensive
printed and oral study, and drug-related instructions by
a clinical research physician. The research physician will
be in contact with the participants after 1, 2 and 6 weeks
of intervention, during which safety and drug account-
ability will be monitored.
Data collection and study procedures
Data will be collected during designated end point visits
at baseline and after 12 weeks of treatment: 1 for the car-
diovascular and renal end points, 1 to collect gastrointes-
tinal data, and 1 visit to perform the MRI (table 1).
These visits will be planned in no particular order.
During the baseline cardiovascular and renal end point
visit, the acute study will be performed. At least 24 h will
be observed between the acute intervention and the
next visit, to allow for washout of the study drug.
Patients participating in the acute pancreatic study will
undergo two additional MRI prior to the start of the
12-week intervention.
Cardiovascular and renal study procedures
Two days prior to this study visit, participants will be
asked to adhere to an standardised sodium chloride
(9–12 g/day) and protein (1.5–2.0 mg/kg/day) intake
in order to minimise diet-induced variation in renal
physiology.76 77 In addition, they will be asked to refrain
from vigorous physical activity and alcohol ingestion for
at least 24 h, and from consuming caffeine for at least
12 h. After an overnight fast, participants will be
instructed to drink 500 mL of water. Intake of all
morning medications, except for metformin, will be
delayed until conclusion of the examination day. After
arrival at the CRU at 7:30, intravenous catheters will be
placed in both arms. Blood and urine will be collected,
and the participant will assume a semirecumbent pos-
ition. Then, resting HRV will be measured using a
Box 1 Inclusion and exclusion criteria
Inclusion criteria
▸ Type 2 diabetes
– Stable dose of oral antihyperglycaemic drugs (metformin
and/or sulfonylurea) for at least 3 months prior to inclusion
– HbA1c 6.5–9.0% DCCT or 48–75 mmol/mol IFCC
▸ Age between 35 and 75 years
▸ Females must be postmenopausal (defined as: no menses
>1 year)
▸ Caucasian
▸ Body mass index 25–40 kg/m2
Exclusion criteria
▸ Use of the following medication: thiazolidinediones, GLP-1
receptor agonists, DPP-4 inhibitors, insulin, glucocorticoids,
non-steroidal anti-inflammatory drugs, antimicrobial agents,
chemotherapeutics or immune suppressants. Patients on
diuretics will only be excluded when these drugs (eg, hydro-
chlorothiazide) cannot be stopped for the duration of the
study
▸ History of pancreatic disease or impaired pancreatic exocrine
function (defined as: use of pancreatic enzymes)
▸ Active liver disease or a threefold elevation of liver enzymes
(AST/ALT) at screening
▸ (History of ) malignancy (with the exception of basal cell
carcinoma)
▸ Estimated-GFR <60 mL/min/1.73 m2; Current urinary tract
infection and active nephritis
▸ Recent (<6 months) history of cardiovascular disease, includ-
ing acute coronary syndrome, stroke, transient ischaemic
neurological disorder; Chronic heart failure (New York Heart
Association grade II-IV) or atrial fibrillation
▸ Alcohol abuse, defined as >4 units day
▸ Allergy to any of the test agents
▸ Complaints compatible with or established gastroparesis and/
or neurogenic bladder
▸ History of or present (severe) mental illness
▸ Inability to understand the study protocol and/or to give
written informed consent
▸ Contraindications for MRI; claustrophobia or presence of
metal objects/implants
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beat-to-beat heart rate monitor. Systemic haemodynamic
parameters will be assessed using an oscillometric blood
pressure measurement device and beat-to-beat blood
pressure monitor. Arterial stiffness will be measured
using applanation tonometry, and microvascular func-
tion with capillary videomicroscopy and laser Doppler
ﬂuxmetry. Bio-impedance analysis (BIA) will be per-
formed to measure body water and fat content.
Subsequently, the renal tests will start. A 10 min
priming with inulin and para-aminohippurate sodium
(PAH) will be followed by continuous infusion of these
renal tracer substances. After 90 min of equilibration,
urine will be collected by spontaneous voiding every
45 min for two time periods, while blood will be
collected before and after each collection period.
Samples will be used to measure GFR (inulin clear-
ance), renal plasma ﬂow (PAH clearance) and tubular
function. Diuresis will be stimulated by oral intake of
10 mL/kg (maximal 1000 mL) tap water during the
equilibration phase, followed by 200 mL of tap water
per hour (ﬁgure 3).
Subsequently, during the baseline end point visit, but
not during the end point visit after 12 weeks of treat-
ment, the acute cardiovascular and renal intervention
study with intravenous administration of exenatide or
placebo will start. After an equilibration period of
60 min to ensure steady-state plasma exenatide concen-
trations,61 urine will be collected by spontaneous voiding
every 45 min for two time periods while blood will be
collected before and after each collection period for
determination of inulin and PAH. In addition, the car-
diovascular tests will be repeated intermittently (see
online supplementary table A and B). Resting HRV will
be assessed after 30, 90 and 165 min. Blood pressure
and systemic haemodynamics will be assessed after 30,
60, 90, 120 and 165 min of intervention. Arterial stiffness
will be assessed after 30, 60, 90 and 160 min, and micro-
vascular function after 110 min.
Finally, at the end of the renal protocol, a meal-test
protocol will start, during which intravenous administra-
tion of exenatide or placebo is continued. A standar-
dised high-fat mixed meal of 905.7 kcal (50 g fat, 75 g
carbohydrates and 36.8 g protein) will be consumed
within 15 min, and cardiovascular and metabolic
changes in the postprandial state will subsequently be
examined. The same meal-test protocol will be per-
formed during the end point visit after 12 weeks of treat-
ment without intravenous exenatide or placebo
administration. Resting HRV will be measured after 30,
60 and 120 min, and blood pressure, systemic haemo-
dynamics and arterial stiffness will be measured every
30 min post meal. Microvascular function will be mea-
sured 90 min after the start of the meal.
Gastrointestinal study procedures
During this visit, three experimental protocols will be
performed simultaneously: (1) a 13C-labelled mixed tri-
glyceride (13C-MTG) breath test (pancreatic digestive
function), (2) a meal-stimulated gallbladder ultrasound
examination (gallbladder emptying rate) and (3) an
acetaminophen absorption kinetic test (gastric emptying
rate). Two days prior to the study visit, participants are
instructed not to take any product that is naturally
enriched with 13C such as corn products, cane sugar,
pineapple and tequila. After an overnight fast, partici-
pants will be instructed to delay all morning medications,
apart from metformin, until conclusion of the examin-
ation day, and arrive at the CRU at 7:30. Body anthropo-
metrics, including weight, height, waist-circumference
and hip-circumference are measured. Participants will
then assume a semirecumbent position, after which BIA
is used to assess body composition. An intravenous
Figure 2 Flow chart of the acute
and prolonged intervention study.
*For the acute cardiovascular and
renal intervention study, patients
are randomised to receive
exenatide or placebo
(parallel-group design). For the
acute pancreatic intervention
study, patients receive exenatide
and placebo, in a randomised
order (cross-over design).
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catheter is inserted into an antecubital vein for blood
sampling. The gallbladder will be visualised by ultrasono-
graphic imaging, recording the length, height and width
of three measurements to calculate baseline gallbladder
volume. Blood will be sampled to determine baseline
serum acetaminophen, and reference breath samples
will be collected using straw and gas collection tubes.
Then, participants will be served a high-fat mixed meal
(420 kcal, 22.4 g fat, 38.6 g carbohydrates and 14.6 g
protein), containing the 13C-MTG stable isotopes
(Euriso-Top, Saint-Aubin Cedex, France) and a standar-
dised acetaminophen solution (Daro, Remark Groep,
Rogat, the Netherlands). This high-fat mixed meal trig-
gers gallbladder contraction. Subsequently, gallbladder
ultrasonographic imaging will be performed every
15 min for 3 h. Postprandially, blood will be drawn every
30 min for 3 h to examine serum acetaminophen levels,
and at set times to assess glucose levels. Every 30 min, a
breath sample will be collected for the 13C-MTG breath
test for 6 h.
MRI procedures
After an overnight fast, participants will be instructed to
delay all morning medications. Participants will arrive at
the CRU between 7:00 and 9:00, and an intravenous
catheter will be inserted into an antecubital vein for
secretin administration. A negative oral contrast agent
(Lumirem, Guerbet, Gorinchem, the Netherlands) is
given to enhance visualisation of the pancreatic duct
system. The MRI protocol will consist of (1) structural
sequences to assess organ anatomy, (2) spectroscopy
sequences to assess hepatic lipid content and (3) MR
cholangiopancreatography (MRCP) sequences for pan-
creatic duct morphology. Moreover, secretin (Secrelux,
Sanochemia Pharmazeutika AG, Vienna, Austria) will be
administered intravenously to induce pancreatic excre-
tion, which is measured and quantiﬁed using MRCP
sequences.
For the acute pancreatic study, the same MRI protocol
is used during concomitant infusion of exenatide or
placebo. After arrival at the CRU between 7:00 and 9:00,
infusion of the study drug or placebo is started. After an
equilibration period of 60 min, the MRI protocol will
start. At least 1 week gap is observed between the MRI
visits.
Safety visits (weeks 2 and 6) and telephone follow-up
(weeks 1 and 9)
At week 2 and 6, after an overnight fast, participants will
be instructed to delay all morning medications, apart
from metformin. Medical history is taken, and drug
accountability is monitored and stimulated. Body
anthropometrics and blood pressure are recorded.
Fasting blood samples will be collected to assess renal
and pancreatic safety parameters at week 2 and 6,
whereas blood, urine and faeces will be stored at week 2
only. At week 1 and 9, medical history is taken and drug
accountability is monitored and stimulated.
Early-term assessments
During all study visits and telephone follow-up, compli-
ance and participant retention will be promoted.
However, in case patients withdraw their participation,
they will be asked to participate in early-term assess-
ments aiming to study as many predeﬁned outcome
measures as possible, with a particular focus on primary
outcomes.
Figure 3 End point visit cardiovascular and renal tests. Schematic overview of the cardiovascular and renal end point visits. (A)
At the baseline end point visit, the acute cardiovascular and renal intervention study is performed; (B) At the 12-week end point
visit, no acute intervention study is performed. PAH, para-amino hippuric acid.
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Quality assurance: data management and monitoring
Outcome data will be collected on hard-copy case report
forms (CRF). The CRF ﬁles will be anonymous, only indi-
cating the participants study number. There will be
double entry of all data into a secure online clinical trial
database programme (OpenClinica LLC, V.3.3, Waltham,
Massachusetts, USA), which complies with all regulations
proposed by the International Conference on
Harmonization of Good Clinical Practice (GCP). The
ﬁnal data set will be exported from OpenClinica, contain-
ing anonymous data, and will principally be available to
study physicians and the principal investigator only.
An independent monitor, provided by the institu-
tional Clinical Research Bureau of the VU University
Medical Center, will oversee the progress of the clinical
trial and ensure that it is conducted, recorded and
reported in accordance with the protocol, standard
operating procedures, GCP and the applicable regula-
tory requirements.
Sample size
Based on previous animal and clinical data on the
effects of GLP-1 administration on HRV, the estimated
GFR and duodenal aspiration measured exocrine pan-
creatic function;56 62 63 assuming 2-sided signiﬁcance
level of 0.05 and a power (1-β) of 80%, we considered
15 participants per treatment arm to be sufﬁcient to
detect statistically signiﬁcant changes in each of our
outcome measures. To allow for a dropout rate of 15%,
we decided to include a total of 60 patients with type 2
diabetes, with 20 per treatment arm for the 12-week
study and 30 participants per treatment arm for the
acute cardiovascular and renal intervention study. Using
the same assumptions, we calculated that 12 patients
would be sufﬁcient for the acute cross-over pancreatic
study. Sample size calculations were performed using an
ANOVA-model with SAS-software (V.9.2, Cary, North
Carolina, USA) for comparing liraglutide and sitagliptin
to placebo. A detailed power analysis is available in the
online supplementary material.
Statistical analyses
A per-protocol analysis is considered the most appropri-
ate approach to examine biological effects of incretin-
based therapies on different organs systems.
To test treatment effects versus placebo, we will
perform multivariable linear regression models (for
single measured end points) and linear mixed models
(for repeatedly measured end points). All analyses will
be corrected for potential between-group baseline
differences. This strategy will be used for both acute and
12-week studies. Log-transformation will be applied
before analysis of non-Gaussian distributed data, as
assessed by visual inspection of histograms and Q-Q
plots. For each end point, we will report the
between-group difference with its 95% CI or SE of the
mean and p value. All analyses will be performed using
SPSS V.22.0 (IBM SPSS Inc, Chicago, Illinois, USA).
MEDICAL ETHICS AND DISSEMINATIONS
The original protocol and all amendments to this proto-
col were approved by the local Ethics Review Board
(2012/391) and the National Central Committee on
Research Involving Human Subjects (NL41701.029.12).
The study will be conducted in accordance with the
Declaration of Helsinki and GCP. All participants will
provide written informed consent before participation.
The study is registered at ClinicalTrials.gov (ID:
NCT01744236).
All patient data will be handled conﬁdentially and
anonymously. Data acquired during the eligibility visit
will be coupled to a screening-visit number. All data
acquired during the study will be coupled to a partici-
pant study number. A code list, with identiﬁer data,
screening numbers and study numbers, will be stored
securely on the institutional server and protected by
passwords only known to the responsible study physi-
cians and principal investigator.
During the study, participants will be monitored by
safety visits and telephone follow-up. All antihyperglycae-
mic study drugs (exenatide, liraglutide and sitagliptin)
have been approved by the Food and Drug
Administration and the European Medicines Agency for
the treatment of type 2 diabetes, and are considered to
be safe. Known adverse effects are nausea, vomiting,
diarrhoea and constipation (especially for exenatide and
liraglutide) and nasopharyngitis (especially for sitaglip-
tin). These adverse events are usually mild and transient.
Both GLP-1 receptor agonists and DPP-4 inhibitors may
induce hypoglycaemia, especially when combined with
sulfonylurea treatment. As described above, care will be
taken to frequently measure blood glucose levels and
sulfonylurea dose will be decreased if regarded neces-
sary. Given the short treatment duration in this cohort
of patients with type 2 diabetes without serious complica-
tions, we expect heart failure and pancreatic risk to be
low. Any reported adverse event will be recorded, while
serious adverse events will additionally be reported to
the Ethics Review Board. Standard clinical care will be
provided to manage the adverse event. In case of pos-
sible damage as a result of participating in this trial, the
loss is covered by institutional insurance.
The protocol has been developed by experts in the
ﬁeld of endocrinology, vascular medicine, nephrology,
gastroenterology and radiology. Members of the
SAFEGUARD consortium have been involved in the
development of this study protocol, and will be involved
in the drafting of the manuscripts. Novo Nordisk A/S
has not been involved in the development of the study
protocol, but will be allowed to comment on medical
accuracy and conﬁdentiality of manuscripts before publi-
cation. The Dutch Kidney Foundation was not involved
in the development of the study protocol, nor will it be
involved in the drafting of the manuscripts. The ﬁndings
from this study will be disseminated through inter-
national peer-reviewed publications, at scientiﬁc confer-
ences, and when considered publically interesting,
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through mass media. Authorship eligibility will be deter-
mined using the guidelines of the International
Committee of Medical Journal Editors.
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